



55 Central Avenue
West Molesey
Surrey KT8 2QZ

T_ +44 (0)20 8481 9016
F_ +44 (0)20 8941 9319
info@quotientdiagnostics.co.uk
www.quotientdiagnostics.co.uk

17th September 2007

PRESS RELEASE

Quotient Diagnostics welcomes new Chief Executive

Quotient Diagnostics Ltd, developers of a new diabetes testing technology, announces that it has appointed Greg Davidson, as its new Chief Executive. He will succeed David Chatterton who has been appointed as the Non-Executive Chairman of the Company.

Greg Davidson, formerly Technical Director of Taylor Hobson, a leading manufacturer of precision measuring instruments has extensive experience in instrumentation and diagnostics projects. Prior to his time at Taylor Hobson his career included managerial posts at Amersham International, Serono Diagnostics, Malvern Instruments and Leica Microsystems. He is a highly qualified physicist, and has a PhD in Radio Astronomy.

Speaking of the appointment, David Chatterton said, 'Greg is well known to the Quotient team, having been associated with our sister company Chelsea Technology in the past. He is ideally qualified to lead the product team through to completion of this important project.'

At the same time Julian Baines, CEO of BBI (British Biocell) plc, is stepping down from the Board and David Evans has taken his place. David is a senior financial director with interests in several medical technology companies and is at the same time Chairman of BBI. BBI is a leading UK name in the diagnostics sector and Quotient's largest shareholder

Quotient's research and development of its Point of Care HbA1c diabetes testing system, Quo-Test, allows an accurate reading, unaffected by variables such as food consumption, in around three minutes. It is anticipated that Quo-Test will be ready for market in early 2008. There is already significant demand for such a test both from Europe and North America and from developing countries where the low cost of Quo-Test will help in managing a rapidly increasing incidence of diabetes.

Greg Davidson has extensive experience of leading and managing teams of scientists and engineers to develop instrumentation and software products in the fields of Medical Diagnostics, Life Science laboratory instrumentation and Industrial Process Control. He relishes the opportunity to become part of the Quotient team and to make the Quo-Test system a significant player in the Diabetes testing market.

Speaking of the appointment of Dr Davidson, George Whitehead, of Quotient backer NESTA, said, "I am delighted to hear that Dr Davidson has been appointed CEO of Quotient Diagnostics. His skills will enable Quotient to remain on target with the development of this innovative product which has the potential for world-wide use."

- **ENDS** -

About Quotient Diagnostics Ltd

Quotient Diagnostics has combined expertise in biochemistry and instrumentation technology to develop a system comprising a low-cost reader and disposable cartridge for the monitoring of diabetes in clinics and surgeries.

This innovative technology, based on fluorescence chemistry developed at St Bartholomew's Hospital, London, is used for measuring the percentage of haemoglobin molecules that are glycated and used clinically to assess the risk of long-term complications in diabetes.

Quotient has employed advanced electronics and optics to develop a high precision desktop reader which can match the performance of a laboratory instrument but operates in a fraction of the time. It combines the simultaneous measurement of absorption and the phenomenon of fluorescence reduction ("quenching") in one step.

Contact: Greg Davidson 020 8481 9016
www.quotientdiagnostics.co.uk

About NESTA

NESTA is the National Endowment for Science, Technology & the Arts. With endowed funds of over £300 million, our mission is to transform the UK's capacity for innovation. We do this in three main ways: by working to build a more pervasive culture of innovation in this country; by providing innovators with access to early stage capital; and by driving forward research into innovation, with a view to influencing policy.

NESTA spokespeople are available for comment and interview. Please contact our press office on +44 (0) 2074382608 or +44 (0) 2074382643